Skip to main content Accessibility help
×
Hostname: page-component-5c6d5d7d68-tdptf Total loading time: 0 Render date: 2024-08-15T14:28:23.521Z Has data issue: false hasContentIssue false

Esketamine

Published online by Cambridge University Press:  19 October 2021

Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Prescriber's Guide
Stahl's Essential Psychopharmacology
, pp. 275 - 280
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Canuso CM, Canuso CM, Singh JB, Singh JB, Fedgchin M, Fedgchin M, et al. Efficacy and safety of esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry 2018;175(7):62030.CrossRefGoogle ScholarPubMed
Daly EJ, Daly EJ, Trivedi MH, Trivedi MH, Janik A, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 2019;76:893903. doi: 10.1001/jamapsychiatry.2019.1189.CrossRefGoogle ScholarPubMed
Fedgchin M, Fedgchin M, Trivedi M, Trivedi M, Daly E, Daly E, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol 2019;22(10):61630.CrossRefGoogle ScholarPubMed
Fu, DJ, Ionescu, DF, Li, X, et al. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind randomized study (ASPIRE I). J Clin Psychiatry 2020;81(3):19m13191.CrossRefGoogle ScholarPubMed
Ionescu, DF, Fu, DJ, Qiu, X, et al. Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicidal ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II). Int J Neuropsychopharmacol 2021;24(1):2231.CrossRefGoogle ScholarPubMed
Ochs-Ross R, Ochs-Ross R, Daly EJ, Daly EJ, Zhang Y, Zhang Y, et al. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression – TRANSFORM-3. Am J Geriatr Psychiatry 2019;28(2):12141.CrossRefGoogle ScholarPubMed
Popova V, Popova V, Daly EJ, Daly EJ, Trivedi M, Trivedi M, et al. Efficacy and safety of flexibly dose esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry 2019;176(6):42838.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Esketamine
  • Stephen M. Stahl, University of California, San Diego
  • Book: Prescriber's Guide
  • Online publication: 19 October 2021
  • Chapter DOI: https://doi.org/10.1017/9781108921275.046
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Esketamine
  • Stephen M. Stahl, University of California, San Diego
  • Book: Prescriber's Guide
  • Online publication: 19 October 2021
  • Chapter DOI: https://doi.org/10.1017/9781108921275.046
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Esketamine
  • Stephen M. Stahl, University of California, San Diego
  • Book: Prescriber's Guide
  • Online publication: 19 October 2021
  • Chapter DOI: https://doi.org/10.1017/9781108921275.046
Available formats
×